This article was originally published in The Gray Sheet
Acquires 1 mil. of Oncometrics Imaging Corp. common stock from Xillix Technologies Corp., making Oncometrics a wholly owned subsidiary of AccuMed. Xillix divested its Oncometrics stock in order to focus on developing its LIFE fluorescent endoscopy system platform for the early detection and localization of cancer. Terms of the transaction were not disclosed
You may also be interested in...
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.
The current pandemic has accelerated the US FDA’s perspective on conducting remote clinical trials. The agency has published an emergency guidance to allow sponsors to continue their work, which a former FDA official says is an indication of where the agency is headed post-COVID-19.